Dena Howard

701 total citations
15 papers, 166 citations indexed

About

Dena Howard is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Dena Howard has authored 15 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Dena Howard's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Dena Howard is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Dena Howard collaborates with scholars based in United Kingdom, Australia and United States. Dena Howard's co-authors include Walter M. Gregory, Julia Brown, Susan Todd, Peter Hillmen, Andy C. Rawstron, Talha Munir, Lucy McParland, Anna Hockaday, Abraham Varghese and David Phillips and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Dena Howard

15 papers receiving 165 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dena Howard United Kingdom 8 106 97 48 34 28 15 166
Kamil Kaplanov Russia 5 67 0.6× 44 0.5× 42 0.9× 21 0.6× 5 0.2× 22 138
Patricia Glynn United States 6 47 0.4× 102 1.1× 18 0.4× 19 0.6× 10 0.4× 10 148
Ingrid Louw United States 6 38 0.4× 29 0.3× 53 1.1× 63 1.9× 6 0.2× 16 167
Catherine Tuglus United States 8 18 0.2× 31 0.3× 20 0.4× 77 2.3× 23 0.8× 12 193
Anastassia Negrouk Belgium 8 33 0.3× 68 0.7× 7 0.1× 6 0.2× 10 0.4× 23 212
Thérèse Aurran France 8 202 1.9× 178 1.8× 80 1.7× 40 1.2× 1 0.0× 19 257
John W. Hayslip United States 6 41 0.4× 70 0.7× 9 0.2× 38 1.1× 2 0.1× 11 222
Nelson Castro Brazil 4 24 0.2× 25 0.3× 50 1.0× 12 0.4× 10 0.4× 11 92
Javier Loscertales Spain 10 226 2.1× 202 2.1× 77 1.6× 67 2.0× 40 264
Shalin Kothari United States 6 33 0.3× 36 0.4× 22 0.5× 18 0.5× 1 0.0× 23 104

Countries citing papers authored by Dena Howard

Since Specialization
Citations

This map shows the geographic impact of Dena Howard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dena Howard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dena Howard more than expected).

Fields of papers citing papers by Dena Howard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dena Howard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dena Howard. The network helps show where Dena Howard may publish in the future.

Co-authorship network of co-authors of Dena Howard

This figure shows the co-authorship network connecting the top 25 collaborators of Dena Howard. A scholar is included among the top collaborators of Dena Howard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dena Howard. Dena Howard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Munir, Talha, Anna Hockaday, Dena Howard, et al.. (2022). Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British Journal of Haematology. 199(5). 707–719. 4 indexed citations
2.
Howard, Dena, Anna Hockaday, Julia Brown, et al.. (2021). A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials. 22(1). 38–38. 7 indexed citations
3.
Beck, Daniel, Dena Howard, Peter Hillmen, et al.. (2018). An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. BMC Research Notes. 11(1). 280–280. 4 indexed citations
4.
Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 18(1). 387–387. 25 indexed citations
5.
Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 31(11). 2416–2425. 21 indexed citations
6.
Munir, Talha, Dena Howard, Lucy McParland, et al.. (2017). Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia. 31(10). 2085–2093. 20 indexed citations
7.
Howard, Dena, Anna Hockaday, Talha Munir, et al.. (2017). GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials. 18(1). 353–353. 3 indexed citations
8.
9.
Gregory, Walter M., Christopher Twelves, Richard H. Bell, et al.. (2016). Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Research and Treatment. 155(2). 303–311. 3 indexed citations
10.
Howard, Dena, Talha Munir, Anna Hockaday, et al.. (2016). Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials. 17(1). 456–456. 1 indexed citations
11.
Rawstron, Andy C., Dena Howard, Lucy McParland, et al.. (2016). Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up. Blood. 128(22). 3226–3226. 8 indexed citations
12.
Robbe, Pauline, Kate Ridout, Jennifer Becq, et al.. (2016). Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot. Blood. 128(22). 2022–2022. 1 indexed citations
13.
14.
Howard, Dena, Julia Brown, Susan Todd, & Walter M. Gregory. (2016). Recommendations on multiple testing adjustment in multi-arm trials with a shared control group. Statistical Methods in Medical Research. 27(5). 1513–1530. 36 indexed citations
15.
Howard, Dena, et al.. (1997). Reduction in the incidence of early rejection in cadaveric renal allograft recipients treated with atgam induction and sequential mycophenolate mofetil. Transplantation Proceedings. 29(1-2). 313–314. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kamil Kaplanov Breakdown of academic impact, for papers by Patricia Glynn Breakdown of academic impact, for papers by Ingrid Louw Breakdown of academic impact, for papers by Catherine Tuglus Breakdown of academic impact, for papers by Anastassia Negrouk Breakdown of academic impact, for papers by Thérèse Aurran Breakdown of academic impact, for papers by John W. Hayslip Breakdown of academic impact, for papers by Nelson Castro Breakdown of academic impact, for papers by Javier Loscertales Breakdown of academic impact, for papers by Shalin Kothari
Rankless by CCL
2026